By Ethan Covey
An experimental 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) appears to be safe and effective compared with existing pneumococcal vaccines, according to data presented at the IDWeek 2020 virtual meeting (abstract 3).
PCV20 is being developed to expand pneumococcal serotype coverage beyond the currently approved 13-valent pneumococcal conjugate vaccine (PCV13) and a 23-valent pneumococcal polysaccharide vaccine (PPSV23).
“Streptococcus pneumoniae causes serious